Ownership

GBC-HpVac is a privately owned company founded in 2016.

GBC-HpVac is focused on the development of GBC-R1 as a preventive and therapeutic first-line therapy against asthma and related allergic diseases, as well as inflammatory bowel conditions such as Crohn's disease and ulcerative colitis. 


GBC-HpVac holds an exclusive, world-wide licence from the University of Zurich. 

Team

Jacques Billy
Jacques Billy, Msc
Member of the Board
Chief Financial Officer at GBC SA
Christine Serratrice
Dr. Christine Serratrice
Chief Medical Officer at GBC SA
 
Jeffrey Shaw
Dr. Jeffrey Shaw
Member of the Board
Chief Executive Officer at GBC SA

Scientific Advisory Board

Prof. Anne Müller
Prof. Anne Müller
Institute for Molecular Cancer Research
University of Zurich
Dr. Sophie Brouard
Dr. Sophie Brouard
co-Director of National Institute of Health and Medical Research (INSERM) UMR 1064 Unit-Nantes
Dr. Marie Bodinier
Dr. Marie Bodinier
Research director at the National Institute of Agronomic Research 
(INRA, BIA unit, Allergy team)
Prof. Erika Von Mutius
Prof. Erika Von Mutius
Professor of Pediatric Allergology
Head of the Asthma and Allergy Department at Children’s Hospital in Munich.  
Leads the Institute for Asthma and Allergy Prevention at Helmholtz Zentrum Munich
Prof. Sébastien Barbarot
Prof. Sébastien Barbarot
Assistant Professor of Dermatology
Head of the Pediatric Dermatology Clinical Trial Unit, Head of the Atopy School in Nantes University Hospital